AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 368.31B, AbbVie(ABBV) trades at $207.70. The stock has a price-to-earnings ratio of 102.39 and currently yields dividends of 3.2%.
On 2026-05-05, AbbVie(ABBV) stock moved within a range of $204.87 to $208.49. With shares now at $207.70, the stock is trading +1.4% above its intraday low and -0.4% below the session's peak.
Trading activity shows a volume of 4.58M, compared to an average daily volume of 7.71M.
The stock's 52-week range extends from a low of $176.57 to a high of $244.81.
The stock's 52-week range extends from a low of $176.57 to a high of $244.81.
ABBV News
Key Points AbbVie posted strong first-quarter results. The company's two biggest growth drivers continue to exceed expectations. AbbVie's overall business lo...
Evercore ISI raised the firm’s price target on AbbVie (ABBV) to $236 from $232 and keeps an Outperform rating on the shares. Unlock hedge fund-level data and p...
Ask 10 different investors what the best stocks are to buy, and you could very well get 10 different answers. There's admittedly a lot of subjectivity involved....
Analyst ratings
71%
of 34 ratingsMore ABBV News
AbbVie (ABBV) just posted first quarter 2026 results that topped Wall Street expectations, with management lifting full year revenue and EPS guidance after soli...
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong gu...
AbbVie delivered a strong earnings beat this week, driven by its immunology portfolio. WSJ’s David Wainer explains why Wall Street is still jittery....
Supporting his view, J.P. Morgan analyst Samik Chatterjee, on April 16, maintained Cisco with an Overweight rating and raised the price target from $95 to $96....
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a...
Analyst Asad Haider of Goldman Sachs assigned a Hold rating on AbbVie, boosting the price target to $244.00. Claim 55% Off TipRanks Unlock hedge fund-level data...
In the first quarter of 2026, AbbVie reported revenue rising to US$15,002 million from US$13,343 million a year earlier, while net income fell to US$695 million...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.